From Lab to Patient: The Journey of a Breakthrough Cancer Drug
The development of a new cancer drug at the University of Alberta shows both the promise and the challenges of drug development.
Availability of Publicly Funded Ibrutinib + Venetoclax for CLL Treatment in Canada
There is some good news to share on the treatment front! Since spring 2025, six provinces in Canada have made publicly funded Ibrutinib + Venetoclax (I+V) combination therapy available for previously untreated CLL patients.
Understanding Communication Styles: Have Better Conversations with Your Doctor
Understanding your preferred communication style can significantly enhance your relationship with your healthcare team and empower you to make informed decisions about your health.
Reflecting on 10 Years of Advances in CLL Treatment
Over a ten-year span, the treatment landscape for chronic lymphocytic leukemia (CLL) has improved dramatically.
From Patient to Partner: How to Do Your Own Research
As a CLL patient, taking an active role in your healthcare can be a game-changer – and doing your own research is a powerful way to start.
Measles and CLL: What You Need to Know
With a flare up of measles cases in Canada, how concerned do we need to be when we have an immune system weakened by CLL?
Treatment Options Beyond BTKi & BCL2
For CLL patients at any age, the idea of running out of treatment options is a big concern. This is especially true for those who are younger and/or raising a family.
Bulletin & Website Upgrades
Changes are afoot in CLL Canada’s online presence, with a new format for our bulletin, an updated website and French language pages.
The 6th CLL Live Patient Conference
Patients and care partners will hear from leading experts in CLL research, treatment and care and share experiences with one another. April 24 to 26, 2025 in Niagara Falls, Ontario.